Inhibitor Financial Statements From 2010 to 2025
| INTI Stock | USD 0.04 0.00 0.00% |
Check Inhibitor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibitor Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Inhibitor financial statements analysis is a perfect complement when working with Inhibitor Therapeutics Valuation or Volatility modules.
Inhibitor |
Inhibitor Therapeutics OTC Stock Shares Outstanding Analysis
Inhibitor Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Inhibitor Therapeutics Shares Outstanding | 376.86 M |
Most of Inhibitor Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibitor Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Inhibitor Therapeutics has 376.86 M of shares currently outstending. This is 108.75% higher than that of the Healthcare sector and 252.68% higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is 34.09% higher than that of the company.
Inhibitor Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Inhibitor Therapeutics's current stock value. Our valuation model uses many indicators to compare Inhibitor Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibitor Therapeutics competition to find correlations between indicators driving Inhibitor Therapeutics's intrinsic value. More Info.Inhibitor Therapeutics is rated fifth overall in return on asset category among its peers. It also is rated fifth overall in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Inhibitor Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inhibitor Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Inhibitor Therapeutics Financial Statements
Investors use fundamental indicators, such as Inhibitor Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Inhibitor Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Inhibitor OTC Stock
Inhibitor Therapeutics financial ratios help investors to determine whether Inhibitor OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inhibitor with respect to the benefits of owning Inhibitor Therapeutics security.